A team of investigators from Duke and the NUS Graduate Medical School in Singapore says they've come up with a novel one-two punch directed against mutant RAS that they believe could have broad potential in fighting cancers.
Lee Kuan Yew, Singapore's first prime minister, who developed the small city-state into a vibrant manufacturing center for petrochemicals, shipping, electronics and a financial hub also leaves a legacy for the drug and biotech industry in Asia that will play out over decades.
Singapore's Ministry of Health said that since the beginning of the year, it has been phasing in an extension of drug subsidies for intermediate and long-term care patients that allows them to buy their treatments at any approved point of care.
GlaxoSmithKline planted its flag in Singapore to build on a close relationship with the government of the wealthy city-state where CEO Andrew Witty worked and lived earlier in his career with the U.K. drugmaker.
When we got started at FierceBiotech more than 13 years ago, our world was actually quite small. The U.S. biotech hubs consumed a lot of our attention, along with the pipelines of all the Big Pharma companies, wherever they were based. But 6 years ago, well after Europe found Fierce, we began to seriously concentrate some added efforts on the continent. The EuroBiotech Report followed, and now we're stepping halfway around the world to focus on Asia with our new, twice-weekly report, FiercePharmaAsia.
Last September, Takeda announced it would be putting vaccines into their own specialty business unit to "accelerate the globalization" of the business. And now, it's positioning the unit geographically to do the same.
Japan's Takeda Pharmaceutical opened an emerging markets and vaccines headquarters in the gleaming new research hub Biopolis on Feb. 25 in the wealthy city-state as it looks to bring a Phase III dengue candidate through trials successfully and challenge Sanofi's lead in the space.
The clinical side of orphan drug use has many twists and turns, not least of which is matching patient ability to pay with the right drug and an openness to understand the dynamics of a "Dallas Buyers Club" approach to use.
A research team at the National University of Singapore has published a paper on a novel strategy to prevent progression of inflammation-associated cancers.
A team of scientists from Singapore's Nanyang Technological University and the Singapore Eye Research Institute is developing an injectable eye medication that utilizes extended-release nanoparticles to treat glaucoma, or fluid buildup in the eye that can lead to blindness.